公开(公告)号：US20220233562A1

公开(公告)日：2022-07-28

申请号：US17723135

申请日：2022-04-18

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs ,  Sami Damak ,  Norbert Sprenger ,  Francis Foata

IPC: A61K31/702 ,  A61P1/00 ,  A61K31/7016

Abstract: A method for reducing nociceptive sensitivity in non-infant humans includes in some examples selecting a non-infant human experiencing a condition and associated nociceptive sensitivity (e.g., irritable bowel syndrome or chronic neuropathic pain). In such examples, the method further includes selecting an effective amount of one or more human milk oligosaccharides (“HMOs”) chosen from the group consisting of 6′-sialyllactose (6′-SL), and a mixture of 6′-SL and lacto-N-tetraose (LNT) and reducing the nociceptive sensitivity by administering the selected effective amount of the chosen HMOs to the non-infant human during an initial phase. In some examples, the method includes activating GPR35 receptors by administering the effective amount of the chosen one or more HMOs. In some examples, the HMOs are a mixture of 6′-SL and LNT that provides a synergistic effect relative to each of the 6′-SL and LNT alone.

公开(公告)号：US11304966B2

公开(公告)日：2022-04-19

申请号：US16956511

申请日：2018-12-19

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs ,  Sami Damak ,  Norbert Sprenger ,  Francis Foata

IPC: A61K31/702 ,  A61P1/00 ,  A61K31/7016

Abstract: The application relates to synthetic compositions and methods for preventing or reducing nociception and/or nociceptive sensitivity in a non-infant human. The human is administered a composition comprising 6′-sialyllactose (6′-SL) and/or lacto-N-tetraose (LNT).

公开(公告)号：US20220054515A1

公开(公告)日：2022-02-24

申请号：US17417049

申请日：2019-12-19

Applicant: Glycom A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Sami Damak ,  Francis Foata ,  Norbert Sprenger

IPC: A61K31/702 ,  A61K9/00

Abstract: A composition and associated packs and methods for (i) promoting gastrointestinal barrier healing in the upper intestinal tract and/or small intestine of a non-infant human suffering from chronic intestinal barrier inflammation, and/or (ii) maintaining remission in the upper intestinal tract and small intestine of a non-infant human suffering from chronic intestinal barrier inflammation. The composition contains an effective amount of a combination of 6′-sialyllactose (6′-SL) and lacto-N-tetraose (LNT).